Quick Answer
Karyopharm Therapeutics Inc. reported Total Assets of $108.42 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $108.42M | -34.1% |
| 2024 | $164.42M | -31.6% |
| 2023 | $240.44M | -32.9% |
| 2022 | $358.17M | +17.3% |
| 2021 | $305.31M | -2.5% |
| 2020 | $313.05M | +6.1% |
| 2019 | $294.96M | -13.5% |
| 2018 | $341.19M | +89.2% |
| 2017 | $180.29M | -0.1% |
| 2016 | $180.38M | -16.3% |
| 2015 | $215.44M | -2.2% |
| 2014 | $220.34M | +39.3% |
| 2013 | $158.23M | +11969.1% |
| 2012 | $1.31M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $96.23M | -49.2% | -8.2% |
| June 30, 2025 | $104.88M | -51.0% | -17.9% |
| March 31, 2025 | $127.71M | -37.5% | -22.3% |
| December 31, 2024 | $164.42M | -31.6% | -13.2% |
| September 30, 2024 | $189.48M | -29.8% | -11.5% |
| June 30, 2024 | $213.98M | -28.2% | +4.7% |
| March 31, 2024 | $204.46M | -37.2% | -15.0% |
| December 31, 2023 | $240.44M | -32.9% | -10.9% |
- Karyopharm Therapeutics Inc. showed a decrease of -34.1% in Total Assets compared to the prior fiscal year.
- Over the 2012–2025 period, Karyopharm Therapeutics Inc.’s total assets has grown by 8169.7% (from $1.31 million to $108.42 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: